We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Proteros and Eisai Co., Ltd Enter into Integrated Lead Discovery Collaboration
News

Proteros and Eisai Co., Ltd Enter into Integrated Lead Discovery Collaboration

Proteros and Eisai Co., Ltd Enter into Integrated Lead Discovery Collaboration
News

Proteros and Eisai Co., Ltd Enter into Integrated Lead Discovery Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Proteros and Eisai Co., Ltd Enter into Integrated Lead Discovery Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Proteros biostructures GmbH announce that the company has entered into a research collaboration with Eisai Co., Ltd (Japan) to identify small molecule inhibitors against a target selected by Eisai in the field of immunology.

Under the agreement Proteros will deliver a novel lead compound applying its integrated lead discovery platform that includes X-Ray structural biology, biophysical screening and profiling, novel fragment libraries and medicinal chemistry expertise.

Dr. Klaus Hinterding, Proteros CSO, stated: "We are very pleased to further deepen our existing relationship with Eisai by being selected as partner for this important program. We look forward to contributing to the success of Eisai's research activities using our unique technology platform."

Advertisement